UNSPSC 51162343: Belladonna/chlorpheniramine/ephedrine/phenobarbital

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.

UNSPSC 51162343 Belladonna/chlorpheniramine/ephedrine/phenobarbital, a Commodity code, shows limited recent activity tied directly to its nominal scope; the recent state and local opportunities tagged under this code predominantly solicit naloxone, safe drug deactivation systems, and generic multi-source pharmaceuticals through cooperative purchasing arrangements rather than the specific combination drugs the code name describes. State and local issuing bodies pursuing this code include county health departments and cooperative purchasing alliances that serve multiple state and local jurisdictions, with procurement structured as competitive bids (IFB) and requests for proposal (RFP) to supply pharmaceutical products to community health facilities and authorized wholesale networks. The work being solicited centers on annual or multi-year supply agreements for pharmaceutical products with detailed compliance requirements around FDA certification, Good Manufacturing Practices (cGMP), Drug Supply Chain Security Act (DSCSA) adherence, and insurance coverage thresholds.

Recent activity concentrates in Florida and the Upper Midwest, with Seminole County, Florida issuing IFB 60459723LAS on June 30, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with a July 26, 2023 response deadline and quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products serving participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. Both solicitations mandate electronic submission, E-Verify compliance, and fixed-fee or competitive-pricing structures; the MMCAP RFP carries heightened scrutiny on price competitiveness (75 percent of evaluation weight) and requires vendors to maintain relationships with authorized wholesalers including AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC.